Up 58% YTD, is Eli Lilly Stock Still a Buy? - Nasdaq

Aug 19, 2024 · Up 58% YTD, is Eli Lilly Stock Still a Buy? August 19, 2024 — 03:14 pm EDT. Written by Ruchi Gupta for Barchart -> Valued at $876.3 billion, Eli Lilly & Co. is a mega-cap ...

CouponFollow Extension

58%
OFF

Up 58% YTD, Is Eli Lilly Stock Still A Buy? - Nasdaq

3 weeks from now

Aug 19, 2024 · Up 58% YTD, is Eli Lilly Stock Still a Buy? August 19, 2024 — 03:14 pm EDT. Written by Ruchi Gupta for Barchart -> Valued at $876.3 billion, Eli Lilly & Co. is a mega-cap ...

nasdaq.com

58%
OFF

Eli Lilly Stock Analysis: Still A Buy After 58% YTD Gain?

3 weeks from now

Aug 19, 2024 · Eli Lilly & Co. (NYSE:LLY) has been a standout performer in the pharmaceutical industry, with its stock surging 58% year-to-date (YTD) and an impressive 68.6% over the past …

upalpha.com

58%
OFF

Up 58% YTD, Is Eli Lilly Stock Still A Buy? - TradingView

3 weeks from now

Aug 19, 2024 · The Street-high price target of $1,117 suggests that Eli Lilly stock could rise as much as 21.4% from here. At nearly 58x forward adjusted earnings, LLY stock is definitely …

tradingview.com

58%
OFF

Up 58% YTD, Is Eli Lilly Stock Still A Buy? - Barchart.com

3 weeks from now

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

barchart.com

5%
OFF

Is Eli Lilly Stock Still A Buy Near All-Time Highs? - Nasdaq

3 weeks from now

Eli Lilly stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in August. With the shares up nearly 68% in the past 52 weeks and 58.5% year-to ...

nasdaq.com

20%
OFF

Eli Lilly Just Hit A Milestone That Disappointed. Here's Why You …

3 weeks from now

Nov 8, 2024 · During Q3, Eli Lilly brought in $11.4 billion in sales, up 20% from a year prior, and non-GAAP (adjusted) EPS of $1.18, which was $0.29 less than what the average of Wall …

fool.com

7%
OFF

Eli Lilly Stock: Why There's Still A Lot To Like In 2025 Despite ...

3 weeks from now

Jan 15, 2025 · That followed a 7% dive on Tuesday after Eli Lilly updated its guidance. The company also said it expects 2025 sales to be in the range of $58 billion to $61 billion, up 32% …

investors.com

$997
OFF

Eli Lilly And Company (LLY) Analyst Ratings - Stock Analysis

3 weeks from now

Jan 24, 2025 · A list of analyst ratings for Eli Lilly (LLY) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Strong Buy. Initiates. $997. Strong …

stockanalysis.com

$45
OFF

Eli Lilly Stock Update: What Investors Should Watch In 2025

3 weeks from now

6 days ago · Investors might keep in mind that Eli Lilly still projects substantial top-line growth for 2024 and especially for 2025. The company expects $45 billion in revenue for 2024 and …

marketbeat.com

17%
OFF

Eli Lilly Stock: 4 Reasons To Buy The Dip After A 17% Drop

3 weeks from now

Jan 14, 2025 · Eli Lilly stock is down 17.75% from its highs as of Jan 10, 2025, even after authorizing a 15 billion stock buyback program. Sales of its GLP-1 drug, Mounjaro, surged …

marketbeat.com

58%
OFF

Up 58% YTD, Is Eli Lilly Stock Still A Buy? - The Globe And Mail

3 weeks from now

Aug 19, 2024 · The Street-high price target of $1,117 suggests that Eli Lilly stock could rise as much as 21.4% from here. At nearly 58x forward adjusted earnings, LLY stock is definitely …

theglobeandmail.com

40%
OFF

Eli Lilly Stock's Correction Brings Opportunity (NYSE:LLY)

3 weeks from now

2 days ago · Intro & Thesis. Occupying over 40% of a fast-growing weight loss drug market, Eli Lilly and Company (NYSE:LLY) stock has been growing at a CAGR of over 30% since 2015 to …

seekingalpha.com

FAQs about Up 58% YTD, is Eli Lilly Stock Still a Buy? - Nasdaq Coupon?

Is Eli Lilly stock a buy?

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation. ...

Should you buy Eli Lilly (ell) now?

Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock. Eli Lilly's latest earnings report was not interpreted positively by the market. Its bestselling drugs reaching a point where supply is meeting demand was the issue. There is still a lot of upcoming growth priced into this stock's valuation. ...

Why did Eli Lilly stock fall 6%?

Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue foreca... ...

Is Eli Lilly's stock overvalued?

Source: Morningstar Direct. Data as of August 14, 2024. With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared with our long-term fair value estimate of $540. Our assumptions for overall biopharma GLP-1 sales in 2031 are close to $170 billion across diabetes ($50 billion), obesity ($85 billion), and overweight ($35 billion). ...

Is Eli Lilly stock hitting new all-time highs?

Eli Lilly's stock is hitting new all-time highs as earnings continue to grow at a rapid rate. Read more about LLY stock here. ...

Should you buy Eli Lilly & Company (LLY) in September 2024?

We previously covered Eli Lilly and Company (NYSE:NYSE: LLY) in September 2024, discussing why we had upgraded the stock as a Buy then, attributed to its secure long-term growth prospects from the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. ...